Brief: ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer
28/04/2025 22:05
April 28 (Reuters) - Oric Pharmaceuticals Inc ORIC.O: ORIC® PHARMACEUTICALS PRESENTS PRECLINICAL DATA TO SUPPORT THE POTENTIAL OF ORIC-944 AS A BEST-IN-CLASS PRC2 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING Source text: ID:nGNXrDQzn Further company coverage: ORIC.O (Reuters.Briefs@thomsonreuters.com)
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows